Unraveling the role of the mitochondrial one-carbon pathway in undifferentiated thyroid cancer by multi-omics analyses

Seong Eun Lee,Seongyeol Park,Shinae Yi,Na Rae Choi,Mi Ae Lim,Jae Won Chang,Ho-Ryun Won,Je Ryong Kim,Hye Mi Ko,Eun-Jae Chung,Young Joo Park,Sun Wook Cho,Hyeong Won Yu,June Young Choi,Min-Kyung Yeo,Boram Yi,Kijong Yi,Joonoh Lim,Jun-Young Koh,Min Jeong Lee,Jun Young Heo,Sang Jun Yoon,Sung Won Kwon,Jong-Lyul Park,In Sun Chu,Jin Man Kim,Seon-Young Kim,Yujuan Shan,Lihua Liu,Sung-A Hong,Dong Wook Choi,Junyoung O. Park,Young Seok Ju,Minho Shong,Seon-Kyu Kim,Bon Seok Koo,Yea Eun Kang

DOI: https://doi.org/10.1038/s41467-024-45366-0

IF: 16.6

2024-02-08

Nature Communications

Abstract:Abstract The role of the serine/glycine metabolic pathway (SGP) has recently been demonstrated in tumors; however, the pathological relevance of the SGP in thyroid cancer remains unexplored. Here, we perform metabolomic profiling of 17 tumor-normal pairs; bulk transcriptomics of 263 normal thyroid, 348 papillary, and 21 undifferentiated thyroid cancer samples; and single-cell transcriptomes from 15 cases, showing the impact of mitochondrial one-carbon metabolism in thyroid tumors. High expression of serine hydroxymethyltransferase-2 (SHMT2) and methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) is associated with low thyroid differentiation scores and poor clinical features. A subpopulation of tumor cells with high mitochondrial one-carbon pathway activity is observed in the single-cell dataset. SHMT2 inhibition significantly compromises mitochondrial respiration and decreases cell proliferation and tumor size in vitro and in vivo. Collectively, our results highlight the importance of the mitochondrial one-carbon pathway in undifferentiated thyroid cancer and suggest that SHMT2 is a potent therapeutic target.

multidisciplinary sciences